What are the minimum requirements for an R03 grant (PAR-09-129)?
• Scientific and/or therapeutic impact of your biological target molecule or pathway • Availability and suitability (or lack thereof) of existing small molecule modulators for the target • HTS readiness of the primary assay including pharmacological validation, reagent availability, assay conditions/protocol, and assay robustness (Z’) • Post-HTS assays including secondary orthogonal assays to rule out false positives of the hits generated from the primary assay, and counter-screening assays to allow prioritization of the hits for further testing and probe development via structure-activity relationships (SAR) study